Dr. Joseph Bonventre is one of the most influential physician scientists of his generation.

He is Chief of the Division of Renal Medicine and Founding Chief of the Engineering in Medicine Division at Brigham and Women’s Hospital, Past-President of the American Society of Nephrology. He led the Kidney Health Initiative Roadmap Initiative for innovative approaches to kidney replacement therapy. He has trained over 150 individuals in his laboratory, many of whom have assumed leadership positions in science and academic medicine. For five years he was Associate Director and for 10 years the Harvard Director of the Harvard-MIT Division of Health Sciences and Technology, where he was responsible for the MD, MD-PhD or PhD training of more than 500 individuals.  He was named one of the three top mentors in the U.S. by postdoctoral fellows in the journal Science in 2004. His laboratory generated a protocol for direct differentiation of kidney organoids from human stem cells that is widely used. His lab has a great deal of experience with various animal models of AKI and chronic kidney disease and discovered KIM-1, a widely used biomarker of kidney injury. The lab also identified cell cycle arrest and the subsequent senescence response of the cell as a key mediator of the transition of acute injury to chronic fibrotic kidney disease. The lab’s work has been cited more than 69,000 times (>26,800 since 2015) and Dr. Bonventre has a citation h-index of 133. He was identified as the most  cited investigator in the field of acute kidney injury and is #4 on the list of  world’s top 2% of scientists by Stanford University in the area of Urology and Nephrology.

See Dr. Bonventre’s full profile here